Clinical Trial Update: A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI) [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study of Ispronicline (TC-1734-112) for age-related memory disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Memory Disorders
• Age-related Memory Impairment

Drugs mentioned

• Ispronicline (Ispronicline)

Snippet

Sponsor: Targacept Inc. | Conditions: Age-Related Memory Disorders | Phase 2 | Status: COMPLETED